Biopharmaceutical company Realm Therapeutics has appointed Sandy Zweifach as a new non-executive director following the retirement of Matthew Hammond and Daniel Hegglin, both of whom served as non-executive directors.
Zweifach joins the biopharma with over 25 years’ experience in the life science industry, with a background in corporate partnering, business development, operations, private and public investing and capital raising.
He is founder, president and chief executive officer of Nuvelution Pharma, a company facilitating the clinical advancement of late stage pharmaceutical and biotechnology assets via a research and development risk-sharing approach that deploys capital and human resources.
Prior to this, Zweifach has served in several leadership roles, including CEO of Ascendancy Healthcare, CEO and president of Pathway Diagnostics and president and CFO of Epoch Biosciences.
Alex Martin, chief executive officer, Realm Therapeutics, said: “I am excited to welcome Sandy to the board.
“His background and experience in both the biopharmaceutical industry and investment banking will be helpful as we progress our pipeline and expand our optionality in 2018 and beyond.”
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...